MECP2 and viral infectious disease: The suppressive efficiency of human MECP2 expression in mCherry+ GABAergic INs within the PrL subregion was validated by immunostaining with anti-MeCP2 antibody 4 weeks after AAV-sgRNA virus infection (Fig. 3C).